Alaunos Therapeutics, Inc.

Name: Alaunos Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

TCRTNasdaqCIK 1107421HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$952.0k, Q2 FY2026

Net income−$952.0k, Q2 FY2026

Alaunos Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Research and development	$m	3.7	0.9	0.1	0.2	0.1	(0.1)	0.3	0.2	0.5	0.4	0.4	0.4
Operating income	$m	(8.7)	(7.9)	(1.7)	(1.2)	(1.2)	(0.8)	(1.1)	(1.0)	(1.2)	(0.9)	(1.0)	(1.0)
Interest expense	$m	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(8.5)	22.6	(1.7)	(1.1)	(1.1)	(0.7)	(1.1)	(1.1)	(1.2)	(0.9)	(1.0)	(1.0)
Diluted EPS	$ per share	(5.30)	not reported	(1.05)	(0.71)	(0.70)	not reported	(0.67)	(0.63)	(0.55)	not reported	(0.59)	(0.41)
Basic EPS	$ per share	(5.30)	not reported	(1.05)	(0.71)	(0.70)	not reported	(0.67)	(0.63)	(0.55)	not reported	(0.59)	(0.41)

Balance sheet

Cash and equivalents$124.0k, Q2 FY2026

Long-term debt$0, FY2024

Shareholders' equity$652.0k, Q2 FY2026

Alaunos Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	11.9	6.1	4.1	2.5	1.7	1.1	0.3	2.9	1.9	1.4	0.4	0.1
Current assets	$m	12.9	8.3	6.0	4.7	3.6	2.8	1.1	3.7	2.7	2.0	1.0	0.7
Total assets	$m	19.4	8.3	6.0	4.7	3.6	2.8	2.1	4.7	3.7	3.0	1.9	1.5
Current liabilities	$m	4.7	2.0	1.2	0.9	0.8	0.7	1.1	1.1	0.9	0.8	0.6	0.9
Total liabilities	$m	5.5	2.0	1.2	0.9	0.8	0.7	1.1	1.1	0.9	0.8	0.6	0.9
Long-term debt	$m	not reported	0.0	0.0	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	13.9	6.3	4.8	3.8	2.7	2.1	1.1	3.7	2.8	2.2	1.3	0.7

Cash flow

Operating cash flow−$300.0k, Q2 FY2026

Capital expenditure$1.0k, Q4 FY2025

Share repurchases$0, Q4 FY2023

Alaunos Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(6,374)	(7,385)	(1,917)	(1,681)	(781)	(592)	(772)	(701)	(844)	(552)	(1,031)	(300)
Capital expenditure	$k	1.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	1.0	not reported	not reported
Share repurchases	$k	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)2.43m, Q2 FY2026

Alaunos Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	215	16.0	1.6	1.6	1.6	1.6	1.6	1.6	1.7	2.2	1.9	2.4

Shares outstanding: 2.54m at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.